PROTACs targeting epigenetic proteins
Acta Materia Medica · 2023 · 2 (4)
DOI: 10.15212/amm-2023-0039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Materia Medica, 2023. Verfasst von Chao Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Changping Laboratory, Beijing 102206, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The field of epigenetics pertains to alterations in gene function that are inherited without changes in the DNA sequence, including histone modifications, post-translational modifications of amino acids, and covalent modifications of DNA bases. These alteration pathways modulate the transformation of genotypes into specific phenotypes. Epigenetics plays major roles in cell growth, development, and differentiation by dynamically regulating gene transcription and ensuring genomic stability. This regulation is performed by three key players: writers, readers, and erasers. In recent years, epigenetic proteins have been found to have crucial roles in epigenetic regulation, and have become important targets in drug research and development. Although targeted therapy is an essential treatment strategy, the effectiveness of targeted drugs is often limited by drug resistance, thus posing a major dilemma in clinical practice. Targeted protein degradation technologies, including proteolysis-targeting chimeras (PROTACs), have great potential in overcoming drug resistance and targeting undruggable targets. PROTACs are gaining increasing attention in the treatment of various epigenetic diseases. In this review, we summarize recently developed degraders targeting epigenetic readers, writers, and erasers. Additionally, we outline new applications for epigenetic protein degraders. Finally, we address several unresolved challenges in the PROTAC field, and suggest potential solutions from our perspective. As the field continues to advance, the integration of these innovative methods holds great promise in addressing the challenges associated with PROTAC development.
Autor:innen und Institutionen
- Changping Laboratory, Beijing 102206, China.
- State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beiji…
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, United States.
- Department of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Förderung
- NCI NIH HHS
Zitieren
APA
Zhang, C., He, Y., Sun, X., Wei, W., Liu, Y., & Rao, Y. (2023). PROTACs targeting epigenetic proteins. Acta Materia Medica, 2(4). https://doi.org/10.15212/amm-2023-0039
Vancouver
Zhang C, He Y, Sun X, Wei W, Liu Y, Rao Y. PROTACs targeting epigenetic proteins. Acta Materia Medica. 2023;2(4). doi:10.15212/amm-2023-0039
BibTeX
@article{Zhang2023,
author = {Zhang, Chao and He, Yuna and Sun, Xiuyun and Wei, Wenyi and Liu, Yanlong and Rao, Yu},
title = {PROTACs targeting epigenetic proteins},
journal = {Acta Materia Medica},
year = {2023},
volume = {2},
number = {4},
doi = {10.15212/amm-2023-0039}
}
EUVIMED